Market Intelligence, Clinical Progress, and High-Purity Reagents for Anemia and Iron Overload Disorders Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TFR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TFR2 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View TFR2 Products |
| Gene Delivery | TFR2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformationally intact cell-based screening. |
View TFR2 Products |
| Benchmark Ab | Anti-TFR2 Recombinant Antibody Recombinant positive control based on clinical candidate sequences. |
View TFR2 Products |
| Validator | TFR2 siRNA Set For knockdown verification and target specificity assays. |
View TFR2 Products |
| Related Target A | TFRC (TFR1) Essential counter-screening target to ensure TFR2 selectivity and avoid systemic toxicity. |
View TFRC Products |
| Related Target B | EPOR (Erythropoietin Receptor) Functional partner in erythroid precursor cells; regulates erythropoiesis. |
View EPOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity Counter-Screening (Avoiding TFR1 cross-reactivity) | Recombinant Human TFR2 and TFRC (TFR1) proteins available with >95% purity and verified molecular weights. |
| Conformational Cell-Based Binding | High-titer Lentivirus for stable overexpressing cell line construction (FACS/Flow Cytometry validation). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) sequence-verified and included. |
| False Positives | Validated siRNA included for gene knockdown specificity checks. |
Live TFR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Transferrin Receptor 2 (TFR2) represents a highly promising frontier in modulating iron homeostasis and erythropoiesis. Unlike its ubiquitously expressed homolog TFR1 (TFRC), TFR2 expression is highly restricted to hepatocytes and erythroid precursor cells. This restricted expression profile makes TFR2 an attractive target for treating anemia of chronic disease (ACD), myelofibrosis-associated anemia, and beta-thalassemia.
The race for TFR2 therapeutics is intensifying, with major players shifting focus from traditional iron-chelating approaches to monoclonal antibodies that block TFR2 signaling to upregulate erythropoiesis. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination strategies, particularly in myelofibrosis patients who exhibit poor responses to JAK inhibitors alone.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Inhibitory) | Disc Medicine (DISC-0974) | Myelofibrosis Anemia, Chronic Kidney Disease Anemia | Selectivity Assay (Need high-purity TFR2 vs TFRC to avoid off-target toxicity) |
| Gene Therapy / RNAi | Academic Institutions | Hereditary Hemochromatosis, Beta-Thalassemia | Knockdown validation (Need sequence-verified TFR2 siRNA) |
| Small Molecule Modulators | Preclinical Stage Biotech | Iron Overload Disorders | Binding kinetics & competition assays (Need stable TFR2 ECD-Fc) |